Verséa will obtain the exclusive right to AXIM’s portfolio of point-of-care (POC) lab testing readers, along with its three diagnostic tests designed to detect biomarkers related to aqueous deficient dry eye disease and allergic conjunctivitis
AXIM Biotechnologies has signed an exclusive global commercial partnership agreement with Verséa Ophthalmics, a division of US-based healthcare company Verséa.
Verséa specialises in the sale and distribution of ocular diagnostic and therapeutic solutions.
Under the terms of the agreement, Verséa will obtain the exclusive commercial right to AXIM’s portfolio of point-of-care (POC) lab testing readers.
In addition, the company will obtain three diagnostic tests designed to detect biomarkers related to aqueous deficient Dry Eye Disease and allergic conjunctivitis.
The three key biomarker tests include the Ocular Immunoglobulin E (IgE) test, the Lactoferrin test, and the Matrix Metalloproteinase 9 (MMP-9) test.
AXIM Biotech chief executive officer John W Huemoeller II said: “This is an exciting day for AXIM, one that has been years in the making – this is the moment where we move from a development-stage biotech company to a revenue-generating healthcare organisation.
“Since the development of our novel ocular diagnostic tests and subsequent success in proving their effectiveness, rather than building an internal team to commercialise the tests, we have been searching for a partner with a solid commercial infrastructure and a firm commitment to eye care, capable of bringing our tests to clinical offices on a global scale.
“With existing sales channels to support their human amniotic membrane therapeutics, Verséa has expressed strong support for our business and a true excitement for adding our technology to their expanding portfolio of healthcare solutions.”
Ocular IgE is a biomarker primarily related to allergic conjunctivitis, and Lactoferrin is a protein found in tears that protects the ocular surface with its antimicrobial properties.
The quantitative test of MMP-9 facilitates objective classification and management of dry eye disease, along with pre-surgical and post-surgical therapeutic guidance.
The tests require a collection of 0.5 microliters of tears, to provide quantitative results within 10 minutes.
Established in 2014, AXIM Biotechnologies is an integrated research and development company focused on the diagnosis of ophthalmological conditions through rapid diagnostic tests.
Verséa Ophthalmics is a business division of Verséa, engaged in the sale and distribution of solutions for diagnosis, treatment, and management of ocular surface diseases.
Verséa CEO and co-founder Sean Fetcho said: “We are delighted to be selected by AXIM as their exclusive partner for the commercialisation of their innovative suite of diagnostic solutions.
“With exclusive global licensing rights to AXIM’s Eye Diagnostics portfolio, Verséa will be introducing a new innovative, rapid, tear-based, POC lab-testing platform designed specifically to assist eye-care clinicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders.”